Samchundang Pharm

Samchundang Pharm is a company operating in the pharmaceutical industry.

SamChunDang Pharm. Co., Ltd. is a top Korean pharmaceutical company specializing in ophthalmic products. With US and EU GMP certifications, SCD leads generic ophthalmic production. Our groundbreaking work includes developing a biosimilar for Eylea (Aflibercept), a macular degeneration treatment, with industry recognition. SCD’s vision extends beyond ophthalmology, as we’re expanding into non-ophthalmic fields like New Drug Delivery System, Oral GLP-1, and Long-acting injections, aiming to revolutionize the global pharmaceutical industry.

Company type

Products and services

Biopharmaceuticals, Finished Dosage Forms

Markets

Middle East Region (e.g. UAE), Central America (e.g. Mexico), East Asia (e.g. China, Japan, Korea), Europe – EU countries, Europe – non EU (e.g. UK, Russia, ex-CIS countries), South America (e.g. Brazil, Colombia), South Asia (e.g. India, Pakistan, Sri Lanka), South East Asia (e.g. Thailand, Philippines, Singapore)

Address

Samchundang Pharm, 351, Hyoryeong-ro,, Seocho-gu, Seoul, Korea, Republic Of, 6643